

Anthony J Lembo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4540029/publications.pdf>

Version: 2024-02-01

169
papers

15,416
citations

25034

57
h-index

17592

121
g-index

174
all docs

174
docs citations

174
times ranked

9773
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical and Psychological Factors Predict Outcome in Patients With Functional Dyspepsia: A Prospective Study. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1251-1258.e1.	4.4	10
2	Symptom severity and clinical characteristics of patients with bloating. <i>Neurogastroenterology and Motility</i> , 2022, 34, e14229.	3.0	8
3	Efficacy of Prucalopride for Chronic Idiopathic Constipation: An Analysis of Participants With Moderate to Very Severe Abdominal Bloating. <i>American Journal of Gastroenterology</i> , 2022, 117, 184-188.	0.4	6
4	Improvement in constipation and diarrhea is associated with improved abdominal pain in patients with functional bowel disorders. <i>Neurogastroenterology and Motility</i> , 2022, 34, e14253.	3.0	2
5	Diminished androgen levels are linked to irritable bowel syndrome and cause bowel dysfunction in mice. <i>Journal of Clinical Investigation</i> , 2022, 132, .	8.2	10
6	Effect of antibiotic pretreatment on bacterial engraftment after Fecal Microbiota Transplant (FMT) in IBS-D. <i>Gut Microbes</i> , 2022, 14, 2020067.	9.8	30
7	Small Intestinal Bacterial Overgrowth Breath Testing in Gastroenterology: Clinical Utility and Pitfalls. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1450-1453.	4.4	3
8	Genotypes of Pain and Analgesia in a Randomized Trial of Irritable Bowel Syndrome. <i>Frontiers in Psychiatry</i> , 2022, 13, 842030.	2.6	3
9	Are They Side Effects? Extraintestinal Symptoms Reported During Clinical Trials of Irritable Bowel Syndrome May Be More Severe at Baseline. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2888-2894.e1.	4.4	2
10	Psychological Predictors of Response to Open-Label Versus Double-Blind Placebo in a Randomized Controlled Trial in Irritable Bowel Syndrome. <i>Psychosomatic Medicine</i> , 2022, 84, 738-746.	2.0	5
11	AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Diarrhea. <i>Gastroenterology</i> , 2022, 163, 137-151.	1.3	43
12	Price Is Right: Exploring Prescription Drug Coverage Barriers for Irritable Bowel Syndrome Using Threshold Pricing Analysis. <i>Digestive Diseases and Sciences</i> , 2021, 66, 4140-4148.	2.3	4
13	Open-label placebo vs double-blind placebo for irritable bowel syndrome: a randomized clinical trial. <i>Pain</i> , 2021, 162, 2428-2435.	4.2	52
14	Management of irritable bowel syndrome with diarrhea: focus on eluxadolone. <i>Current Medical Research and Opinion</i> , 2021, 37, 567-578.	1.9	6
15	Abdominal Pain and Depression, Not Bowel Habits, Predict Health Care Utilization in Patients With Functional Bowel Disorders. <i>American Journal of Gastroenterology</i> , 2021, 116, 1720-1726.	0.4	14
16	Improving Medication Tolerance. <i>Journal of Clinical Gastroenterology</i> , 2021, Publish Ahead of Print, .	2.2	4
17	Editorial: topiramate for cyclic vomiting syndrome“for refractory patients only?. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 500-501.	3.7	1
18	Peppermint Oil Treatment for Irritable Bowel Syndrome: A Randomized Placebo-Controlled Trial. <i>American Journal of Gastroenterology</i> , 2021, 116, 2279-2285.	0.4	19

#	ARTICLE	IF	CITATIONS
19	Evaluating the Impact of Cost on the Treatment Algorithm for Chronic Idiopathic Constipation: Cost-Effectiveness Analysis. <i>American Journal of Gastroenterology</i> , 2021, 116, 2118-2127.	0.4	11
20	Emerging Role of the Gut Microbiome in Irritable Bowel Syndrome. <i>Gastroenterology Clinics of North America</i> , 2021, 50, 523-545.	2.2	19
21	619 HIGH DISCOVERY RATE OF GASTRODUODENAL EOSINOPHILIA BUT NOT EOSINOPHILIC ESOPHAGITIS IN PATIENTS WITH CHRONIC GASTROINTESTINAL SYMPTOMS. <i>Ecological Management and Restoration</i> , 2021, 34, .	0.4	0
22	Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 26-Week, Placebo-Controlled Phase 3 Trial (T3MPO-2). <i>American Journal of Gastroenterology</i> , 2021, 116, 1294-1303.	0.4	23
23	Therapeutics, Placebo and the Importance of Hard Outcomes in Irritable Bowel Syndrome Research. <i>Clinical Gastroenterology and Hepatology</i> , 2021, , .	4.4	0
24	Genomic Effects Associated With Response to Placebo Treatment in a Randomized Trial of Irritable Bowel Syndrome. <i>Frontiers in Pain Research</i> , 2021, 2, 775386.	2.0	3
25	Review Article: Current and future treatment approaches for IBS with diarrhoea (IBSâ€œD) and IBS mixed pattern (IBSâ€œM). <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, S63-S74.	3.7	13
26	The international anorectal physiology working group (IAPWG) recommendations: Standardized testing protocol and the London classification for disorders of anorectal function. <i>Neurogastroenterology and Motility</i> , 2020, 32, e13679.	3.0	184
27	Use of Treatments for Irritable Bowel Syndrome and Patient Satisfaction Based on the IBS in America Survey. <i>Gastroenterology</i> , 2020, 158, 786-788.e1.	1.3	33
28	Can an Evidence-Based Approach Improve the Patient-Physician Relationship?. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 31.	7.4	1
29	Information- and Health-care Seeking Behaviors in Patients With Irritable Bowel Syndrome. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2840-2842.	4.4	5
30	Similarities in Clinical and Psychosocial Characteristics of Functional Diarrhea and Irritable Bowel Syndrome With Diarrhea. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 399-405.e1.	4.4	19
31	Difference in Defecation Desire Between Patients With and Without Chronic Constipation: A Large-Scale Internet Survey. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00230.	2.5	8
32	Fecal Urgency: Clinical and Manometric Characteristics in Patients With and Without Diarrhea. <i>Digestive Diseases and Sciences</i> , 2020, 65, 3679-3687.	2.3	5
33	Effects of the vibrating capsule on colonic circadian rhythm and bowel symptoms in chronic idiopathic constipation. <i>Neurogastroenterology and Motility</i> , 2020, 32, e13890.	3.0	19
34	Brief Behavioral Therapy for Insomnia in Patients with Irritable Bowel Syndrome: A Pilot Study. <i>Digestive Diseases and Sciences</i> , 2020, 65, 3260-3270.	2.3	9
35	Symptom Severity, Mood, and Healthcare Use Are Associated With Satisfaction in Patients With Irritable Bowel Syndrome. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2945-2951.e1.	4.4	6
36	Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 12-Week, Placebo-Controlled Phase 3 Trial (T3MPO-1). <i>American Journal of Gastroenterology</i> , 2020, 115, 281-293.	0.4	59

#	ARTICLE	IF	CITATIONS
37	Effects of treatment with eluxadoline on abdominal pain in patients with IBS: Additional post hoc analyses of Phase 3 trials. <i>Neurogastroenterology and Motility</i> , 2020, 32, e13774.	3.0	7
38	Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing/Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study. <i>CNS Drugs</i> , 2020, 34, 185-196.	5.9	80
39	Microbiome and Its Role in Irritable Bowel Syndrome. <i>Digestive Diseases and Sciences</i> , 2020, 65, 829-839.	2.3	111
40	Abdominal Pain Response to Rifaximin in Patients With Irritable Bowel Syndrome With Diarrhea. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00144.	2.5	12
41	Editorial: symptom improvement does not equal satisfaction with treatment for constipation. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 909-910.	3.7	4
42	Overall safety of relamorelin in adults with diabetic gastroparesis: Analysis of phase 2a and 2b trial data. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1139-1148.	3.7	26
43	Impact of patient and disease characteristics on the efficacy and safety of eluxadoline for IBS-D: a subgroup analysis of phase III trials. <i>Therapeutic Advances in Gastroenterology</i> , 2019, 12, 175628481984129.	3.2	12
44	The Clinical Accuracy of the HLMANN fCAL ELISA in the Differentiation of Inflammatory Bowel Disease From Irritable Bowel Syndrome: A Multicenter Prospective Case-Control Study. <i>Crohn's & Colitis</i> 360, 2019, 1, .	1.1	2
45	Effects of Irritable Bowel Syndrome on Daily Activities Vary Among Subtypes Based on Results From the IBS in America Survey. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2471-2478.e3.	4.4	65
46	Obesity is associated with significantly increased risk for diarrhoea after controlling for demographic, dietary and medical factors: a cross-sectional analysis of the 2009-2010 National Health and Nutrition Examination Survey. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 1019-1024.	3.7	21
47	Serum zonulin is elevated in IBS and correlates with stool frequency in IBS. <i>United European Gastroenterology Journal</i> , 2019, 7, 709-715.	3.8	34
48	Pelvic Floor Symptom Related Distress in Chronic Constipation Correlates With a Diagnosis of Irritable Bowel Syndrome With Constipation and Constipation Severity but Not Pelvic Floor Dyssynergia. <i>Journal of Neurogastroenterology and Motility</i> , 2019, 25, 129-136.	2.4	7
49	Chronic Diarrhea and Constipation Are More Common in Depressed Individuals. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2696-2703.	4.4	56
50	Safety and tolerability of linaclotide for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation: pooled Phase 3 analysis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 397-406.	3.0	13
51	Fecal urgency is common in constipated patients and is associated with anxiety. <i>Neurogastroenterology and Motility</i> , 2019, 31, e13545.	3.0	11
52	Randomized Clinical Trial: Crofelemer Treatment in Women With Diarrhea-Predominant Irritable Bowel Syndrome. <i>Clinical and Translational Gastroenterology</i> , 2019, 10, e00110.	2.5	15
53	Safety of Endoscopy in Heritable Connective Tissue Disorders. <i>American Journal of Gastroenterology</i> , 2019, 114, 1343-1345.	0.4	3
54	Prevalence of Chronic Constipation and Chronic Diarrhea in Diabetic Individuals in the United States. <i>American Journal of Gastroenterology</i> , 2019, 114, 135-142.	0.4	49

#	ARTICLE	IF	CITATIONS
55	Significant Morbidity and Mortality Associated with Fecal Impaction in Patients Who Present to the Emergency Department. <i>Digestive Diseases and Sciences</i> , 2019, 64, 1320-1327.	2.3	15
56	The Prevalence of Gastroesophageal Reflux in Patients With Excessive Central Airway Collapse. <i>Chest</i> , 2019, 155, 540-545.	0.8	12
57	Rifaximin is associated with modest, transient decreases in multiple taxa in the gut microbiota of patients with diarrhoea-predominant irritable bowel syndrome. <i>Gut Microbes</i> , 2019, 10, 22-33.	9.8	57
58	Demographic and Dietary Associations of Chronic Diarrhea in a Representative Sample of Adults in the United States. <i>American Journal of Gastroenterology</i> , 2018, 113, 593-600.	0.4	39
59	Emergency department utilisation for inflammatory bowel disease in the United States from 2006 to 2014. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 913-921.	3.7	34
60	Risk Factors for Fecal Urgency Among Individuals With and Without Diarrhea, Based on Data From the National Health and Nutrition Examination Survey. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1450-1458.e2.	4.4	18
61	Factors Associated With Response to Placebo in Patients With Irritable Bowel Syndrome and Constipation. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1738-1744.e1.	4.4	33
62	Efficacy of Treatments for Opioid-Induced Constipation: Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1569-1584.e2.	4.4	76
63	Low-Dose Linaclotide (72 µg) for Chronic Idiopathic Constipation: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial. <i>American Journal of Gastroenterology</i> , 2018, 113, 105-114.	0.4	55
64	Reduction in pain: Is it worth the gain? The effect of opioids on the GI tract. <i>Neurogastroenterology and Motility</i> , 2018, 30, e13367.	3.0	11
65	Clinical and manometric characteristics of women with paradoxical puborectalis syndrome. <i>United European Gastroenterology Journal</i> , 2018, 6, 1578-1585.	3.8	1
66	A169 EFFICACY AND SAFETY OF ELUXADOLINE IN ELDERLY PATIENTS WITH IRRITABLE BOWEL SYNDROME WITH DIARRHEA. <i>Journal of the Canadian Association of Gastroenterology</i> , 2018, 1, 252-253.	0.3	1
67	Sleep Disturbances Are Commonly Reported Among Patients Presenting to a Gastroenterology Clinic. <i>Digestive Diseases and Sciences</i> , 2018, 63, 2983-2991.	2.3	35
68	Irritable Bowel Syndrome: An Infectious Disease?. <i>Gastroenterology</i> , 2017, 152, 936-938.	1.3	1
69	Tenapanor Treatment of Patients With Constipation-Predominant Irritable Bowel Syndrome: A Phase 2, Randomized, Placebo-Controlled Efficacy and Safety Trial. <i>American Journal of Gastroenterology</i> , 2017, 112, 763-774.	0.4	80
70	Eluxadoline Efficacy in IBS-D Patients Who Report Prior Loperamide Use. <i>American Journal of Gastroenterology</i> , 2017, 112, 924-932.	0.4	43
71	Reply. <i>Gastroenterology</i> , 2017, 152, 1630-1631.	1.3	0
72	Assessment of Anti-vinculin and Anti-cytolethal Distending Toxin B Antibodies in Subtypes of Irritable Bowel Syndrome. <i>Digestive Diseases and Sciences</i> , 2017, 62, 1480-1485.	2.3	35

#	ARTICLE	IF	CITATIONS
73	Gender differences in chronic constipation on anorectal motility. <i>Neurogastroenterology and Motility</i> , 2017, 29, e12980.	3.0	18
74	Pseudoachalasia Secondary to Thoracic Aortic Aneurysm. <i>Annals of Thoracic Surgery</i> , 2017, 103, e517-e518.	1.3	7
75	Opioids in Gastroenterology: Treating Adverse Effects and Creating Therapeutic Benefits. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1338-1349.	4.4	110
76	Editorial: <sc>ONO</sc>â€²952 in irritable bowel syndrome with diarrhoea. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 1004-1005.	3.7	1
77	Repeat Rifaximin for Irritable Bowel Syndrome: No Clinically Significant Changes in Stool Microbial Antibiotic Sensitivity. <i>Digestive Diseases and Sciences</i> , 2017, 62, 2455-2463.	2.3	43
78	Emergency Department Burden of Diverticulitis in the USA, 2006â€²2013. <i>Digestive Diseases and Sciences</i> , 2017, 62, 2694-2703.	2.3	53
79	Hydrogen and Methane-Based Breath Testing in Gastrointestinal Disorders: The North American Consensus. <i>American Journal of Gastroenterology</i> , 2017, 112, 775-784.	0.4	525
80	Repeat treatment with rifaximin improves irritable bowel syndrome-related quality of life: a secondary analysis of a randomized, double-blind, placebo-controlled trial. <i>Therapeutic Advances in Gastroenterology</i> , 2017, 10, 689-699.	3.2	18
81	Evaluation and performance of a newly developed patient-reported outcome instrument for diarrhea-predominant irritable bowel syndrome in a clinical study population. <i>Therapeutic Advances in Gastroenterology</i> , 2017, 10, 673-687.	3.2	4
82	Editorial: latent class analysis to improve confidence in the diagnosis of <sc>IBS</sc>. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 1267-1268.	3.7	1
83	Chronic constipation. <i>Nature Reviews Disease Primers</i> , 2017, 3, 17095.	30.5	203
84	Open-label versus double-blind placebo treatment in irritable bowel syndrome: study protocol for a randomized controlled trial. <i>Trials</i> , 2017, 18, 234.	1.6	43
85	Irritable bowel syndrome and diet. <i>Gastroenterology Report</i> , 2017, 5, 11-19.	1.3	37
86	Pharmacologic, Pharmacokinetic, and Pharmacogenomic Aspects of Functional Gastrointestinal Disorders. <i>Gastroenterology</i> , 2016, 150, 1319-1331.e20.	1.3	26
87	Development and Validation of the Rome IV Diagnostic Questionnaire for Adults. <i>Gastroenterology</i> , 2016, 150, 1481-1491.	1.3	400
88	Bowel Disorders. <i>Gastroenterology</i> , 2016, 150, 1393-1407.e5.	1.3	1,912
89	Relamorelin Reduces Vomiting Frequency and Severity and Accelerates Gastric Emptying in Adults With Diabetic Gastroparesis. <i>Gastroenterology</i> , 2016, 151, 87-96.e6.	1.3	112
90	Editorial: mixed soluble fibre in chronic constipation â€² something new?. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 302-303.	3.7	1

#	ARTICLE	IF	CITATIONS
91	Repeat Treatment With Rifaximin Is Safe and Effective in Patients With Diarrhea-Predominant Irritable Bowel Syndrome. <i>Gastroenterology</i> , 2016, 151, 1113-1121.	1.3	209
92	OC-070...Eluxadoline Demonstrates Efficacy for the Treatment of Irritable Bowel Syndrome (IBS) with Diarrhoea (IBS-D) Among Multiple Clinically Relevant Patient Subgroups. <i>Gut</i> , 2016, 65, A42-A43.	12.1	1
93	Eluxadoline for Irritable Bowel Syndrome with Diarrhea. <i>New England Journal of Medicine</i> , 2016, 374, 242-253.	27.0	249
94	Fecal Impaction in the Emergency Department. <i>Journal of Clinical Gastroenterology</i> , 2016, 50, 572-577.	2.2	24
95	Comparison of adequate relief with symptom, global, and responder endpoints in linaclotide phase 3 trials in IBS. <i>United European Gastroenterology Journal</i> , 2015, 3, 53-62.	3.8	11
96	Consensus Recommendations on Initiating Prescription Therapies for Opioid-Induced Constipation. <i>Pain Medicine</i> , 2015, 16, 2324-2337.	1.9	95
97	Complementary and Alternative Medicine Use Is Prevalent Among Patients with Gastrointestinal Diseases. <i>Digestive Diseases and Sciences</i> , 2015, 60, 1883-1888.	2.3	111
98	Response to Pasalar et al.. <i>American Journal of Gastroenterology</i> , 2015, 110, 936.	0.4	0
99	Su1383 Effects of Eluxadoline on Abdominal Pain in Patients With Irritable Bowel Syndrome With Diarrhea: Results of 2 Phase 3 Clinical Trials. <i>Gastroenterology</i> , 2015, 148, S-493.	1.3	1
100	Emergency Department Burden of Constipation in the United States from 2006 to 2011. <i>American Journal of Gastroenterology</i> , 2015, 110, 572-579.	0.4	90
101	Novel Therapies in IBS-D Treatment. <i>Current Treatment Options in Gastroenterology</i> , 2015, 13, 432-440.	0.8	13
102	Inpatient burden of childhood functional GI disorders in the USA: an analysis of national trends in the USA from 1997 to 2009. <i>Neurogastroenterology and Motility</i> , 2015, 27, 684-692.	3.0	81
103	Current and emerging drug options in the treatment of diarrhea predominant irritable bowel syndrome. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 2781-2792.	1.8	11
104	Development and Validation of a Biomarker for Diarrhea-Predominant Irritable Bowel Syndrome in Human Subjects. <i>PLoS ONE</i> , 2015, 10, e0126438.	2.5	114
105	Linaclotide in Chronic Idiopathic Constipation Patients with Moderate to Severe Abdominal Bloating: A Randomized, Controlled Trial. <i>PLoS ONE</i> , 2015, 10, e0134349.	2.5	61
106	Patient-Provider Interactions Affect Symptoms in Gastroesophageal Reflux Disease: A Pilot Randomized, Double-Blind, Placebo-Controlled Trial. <i>PLoS ONE</i> , 2015, 10, e0136855.	2.5	25
107	Qualitative Development of a Patient-Reported Outcome Symptom Measure in Diarrhea-Predominant Irritable Bowel Syndrome. <i>Clinical and Translational Gastroenterology</i> , 2014, 5, e59.	2.5	12
108	Introduction: Opioid-Induced Constipation. <i>American Journal of Gastroenterology Supplements (Print)</i> , 2014, 2, 2-2.	0.7	1

#	ARTICLE	IF	CITATIONS
109	Irritable Bowel Syndrome subtypes: constipation, diarrhea and mixed bowel pattern: <i>Tertium datur</i> . <i>Neurogastroenterology and Motility</i> , 2014, 26, 1-2.	3.0	1
110	Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double-blind, placebo-controlled trials. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 1161-1168.	3.7	90
111	Complementary and Alternative Medicine Use by US Adults With Gastrointestinal Conditions: Results from the 2012 National Health Interview Survey. <i>American Journal of Gastroenterology</i> , 2014, 109, 1705-1711.	0.4	68
112	Opioid-Induced Bowel Dysfunction: Epidemiology, Pathophysiology, Diagnosis and Initial Therapeutic Approach. <i>American Journal of Gastroenterology Supplements (Print)</i> , 2014, 2, 31-37.	0.7	91
113	American Gastroenterological Association Institute Technical Review on the Pharmacological Management of Irritable Bowel Syndrome. <i>Gastroenterology</i> , 2014, 147, 1149-1172.e2.	1.3	113
114	Efficacy of Prebiotics, Probiotics, and Synbiotics in Irritable Bowel Syndrome and Chronic Idiopathic Constipation: Systematic Review and Meta-analysis. <i>American Journal of Gastroenterology</i> , 2014, 109, 1547-1561.	0.4	595
115	American College of Gastroenterology Monograph on the Management of Irritable Bowel Syndrome and Chronic Idiopathic Constipation. <i>American Journal of Gastroenterology</i> , 2014, 109, S2-S26.	0.4	503
116	Editorial: IBS With Constipation, Functional Constipation, Painful and Non-Painful Constipation: e Pluribus in Plures?. <i>American Journal of Gastroenterology</i> , 2014, 109, 885-886.	0.4	11
117	Effect of Antidepressants and Psychological Therapies, Including Hypnotherapy, in Irritable Bowel Syndrome: Systematic Review and Meta-Analysis. <i>American Journal of Gastroenterology</i> , 2014, 109, 1350-1365.	0.4	335
118	Opioid-Induced Bowel Dysfunction. <i>Current Gastroenterology Reports</i> , 2013, 15, 344.	2.5	55
119	Inpatient discharge rates for the irritable bowel syndrome – an analysis of national trends in the United States from 1997 to 2010. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 1338-1346.	3.7	14
120	Diagnostic testing for dyssynergic defecation in chronic constipation: meta-analysis. <i>Neurogastroenterology and Motility</i> , 2013, 25, 509.	3.0	71
121	Phase 2b, randomized, double-blind 12-week studies of TZIP-102, a ghrelin receptor agonist for diabetic gastroparesis. <i>Neurogastroenterology and Motility</i> , 2013, 25, e705-17.	3.0	94
122	PWE-027...Mediation Analysis Supports a Direct Effect of Linaclotide (LIN) on Abdominal Pain (AP) Relief Independent of Constipation Improvement: Abstract PWE-027 Table. <i>Gut</i> , 2013, 62, A141.1-A141.	12.1	0
123	Successful Treatment with Methylnaltrexone and IVIG for Paraneoplastic Syndrome-Associated Intestinal Pseudo-Obstruction. <i>Gastroenterology and Hepatology</i> , 2013, 9, 48-51.	0.1	2
124	Linaclotide for Irritable Bowel Syndrome With Constipation: A 26-Week, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Efficacy and Safety. <i>American Journal of Gastroenterology</i> , 2012, 107, 1702-1712.	0.4	374
125	A 12-Week, Randomized, Controlled Trial With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Linaclotide in Irritable Bowel Syndrome With Constipation. <i>American Journal of Gastroenterology</i> , 2012, 107, 1714-1724.	0.4	318
126	Evaluation of Harm in the Pharmacotherapy of Irritable Bowel Syndrome. <i>American Journal of Medicine</i> , 2012, 125, 381-393.	1.5	68

#	ARTICLE	IF	CITATIONS
127	Complementary and Alternative Medicine for the Irritable Bowel Syndrome. <i>Gastroenterology Clinics of North America</i> , 2011, 40, 245-253.	2.2	26
128	Severity in Irritable Bowel Syndrome: A Rome Foundation Working Team Report. <i>American Journal of Gastroenterology</i> , 2011, 106, 1749-1759.	0.4	182
129	Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation. <i>New England Journal of Medicine</i> , 2011, 364, 22-32.	27.0	880
130	Evolving concepts in chronic constipation in Europe and elsewhere: not worlds apart. <i>Neurogastroenterology and Motility</i> , 2011, 23, 693-696.	3.0	5
131	Long-Term Safety and Effectiveness of Lubiprostone, a Chloride Channel (ClC-2) Activator, in Patients with Chronic Idiopathic Constipation. <i>Digestive Diseases and Sciences</i> , 2011, 56, 2639-45.	2.3	94
132	Two Randomized Trials of Linaclotide for Chronic Constipation. <i>New England Journal of Medicine</i> , 2011, 365, 527-536.	27.0	322
133	Which patients improve: Characteristics increasing sensitivity to a supportive patient-practitioner relationship. <i>Social Science and Medicine</i> , 2010, 70, 479-484.	3.8	42
134	Characterizing abdominal pain in IBS: guidance for study inclusion criteria, outcome measurement and clinical practice. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 32, 1192-1202.	3.7	30
135	Efficacy of Linaclotide for Patients With Chronic Constipation. <i>Gastroenterology</i> , 2010, 138, 886-895.e1.	1.3	216
136	Linaclotide Improves Abdominal Pain and Bowel Habits in a Phase IIb Study of Patients With Irritable Bowel Syndrome With Constipation. <i>Gastroenterology</i> , 2010, 139, 1877-1886.e2.	1.3	209
137	Placebos without Deception: A Randomized Controlled Trial in Irritable Bowel Syndrome. <i>PLoS ONE</i> , 2010, 5, e15591.	2.5	672
138	Psychiatric Disorder, Irritable Bowel Syndrome and Extra-Intestinal Symptoms in a Population-Based Sample of Twins. <i>American Journal of Gastroenterology</i> , 2009, 104, 686-694.	0.4	19
139	Adequate Relief in a Treatment Trial With IBS Patients: A Prospective Assessment. <i>American Journal of Gastroenterology</i> , 2009, 104, 912-919.	0.4	48
140	A Treatment Trial of Acupuncture in IBS Patients. <i>American Journal of Gastroenterology</i> , 2009, 104, 1489-1497.	0.4	116
141	Treatment of <i>Helicobacter pylori</i> infection with intra-gastric violet light phototherapy: A pilot clinical trial. <i>Lasers in Surgery and Medicine</i> , 2009, 41, 337-344.	2.1	68
142	“Maybe I Made Up the Whole Thing”: Placebos and Patients’ Experiences in a Randomized Controlled Trial. <i>Culture, Medicine and Psychiatry</i> , 2009, 33, 382-411.	1.2	125
143	Measuring irritable bowel syndrome patient-reported outcomes with an abdominal pain numeric rating scale. <i>Alimentary Pharmacology and Therapeutics</i> , 2009, 30, 1159-1170.	3.7	93
144	Delayed Radionucleotide Gastric Emptying Studies Predict Morbidity in Diabetics With Symptoms of Gastroparesis. <i>Gastroenterology</i> , 2009, 137, 445-452.	1.3	132

#	ARTICLE	IF	CITATIONS
145	Pilot Study on the Effect of Linaclotide in Patients With Chronic Constipation. <i>American Journal of Gastroenterology</i> , 2009, 104, 125-132.	0.4	115
146	Psychiatric Disorder, Irritable Bowel Syndrome, and Extra-Intestinal Symptoms in a Population-Based Sample of Twins. <i>American Journal of Gastroenterology</i> , 2009, 104, 686-694.	0.4	2
147	Opioid-induced bowel dysfunction. <i>Current Treatment Options in Gastroenterology</i> , 2008, 11, 11-18.	0.8	7
148	Endoscopic full-thickness plication for the treatment of GERD: Five-year long-term multicenter results. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2008, 22, 326-332.	2.4	57
149	Effectiveness of recruitment in clinical trials: An analysis of methods used in a trial for irritable bowel syndrome patients. <i>Contemporary Clinical Trials</i> , 2008, 29, 241-251.	1.8	37
150	Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome. <i>BMJ: British Medical Journal</i> , 2008, 336, 999-1003.	2.3	1,001
151	Highlights from the 2007 ACG. <i>Gastroenterology and Hepatology</i> , 2008, 4, 118-22.	0.1	0
152	Influence of genetics on irritable bowel syndrome, gastroesophageal reflux and dyspepsia: a twin study. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 25, 1343-1350.	3.7	136
153	Endoscopic full-thickness plication for the treatment of GERD: long-term multicenter results. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2007, 21, 439-444.	2.4	57
154	Endoscopic Full-Thickness Plication for the Treatment of Gastroesophageal Reflux Disease: A Randomized, Sham-Controlled Trial. <i>Gastroenterology</i> , 2006, 131, 704-712.	1.3	145
155	Investigating placebo effects in irritable bowel syndrome: A novel research design. <i>Contemporary Clinical Trials</i> , 2006, 27, 123-134.	1.8	24
156	Current gut-directed therapies for irritable bowel syndrome. <i>Current Treatment Options in Gastroenterology</i> , 2006, 9, 314-323.	0.8	17
157	Peripheral Opioids for Functional GI Disease: A Reappraisal. <i>Digestive Diseases</i> , 2006, 24, 91-98.	1.9	13
158	A 54-Year-Old Woman With Constipation-Predominant Irritable Bowel Syndrome. <i>JAMA - Journal of the American Medical Association</i> , 2006, 295, 925.	7.4	2
159	Endoscopic full-thickness plication for the treatment of GERD: 12-month follow-up for the North American open-label trial. <i>Gastrointestinal Endoscopy</i> , 2005, 61, 643-649.	1.0	86
160	Irritable Bowel Syndrome: Toward an Understanding of Severity. <i>Clinical Gastroenterology and Hepatology</i> , 2005, 3, 717-725.	4.4	91
161	Review of tegaserod in the treatment of irritable bowel syndrome. <i>Expert Opinion on Pharmacotherapy</i> , 2004, 5, 2369-2379.	1.8	16
162	Effect of alosetron on bowel urgency and global symptoms in women with severe, diarrhea-predominant irritable bowel syndrome: Analysis of two controlled trials. <i>Clinical Gastroenterology and Hepatology</i> , 2004, 2, 675-682.	4.4	60

#	ARTICLE	IF	CITATIONS
163	Effect of tegaserod in chronic constipation: A randomized, double-blind, controlled trial. <i>Clinical Gastroenterology and Hepatology</i> , 2004, 2, 796-805.	4.4	164
164	Endoscopic full-thickness plication for the treatment of GERD: a multicenter trial. <i>Gastrointestinal Endoscopy</i> , 2004, 59, 163-171.	1.0	117
165	Irritable Bowel Syndrome Medications Side Effects Survey. <i>Journal of Clinical Gastroenterology</i> , 2004, 38, 776-781.	2.2	28
166	Chronic Constipation. <i>New England Journal of Medicine</i> , 2003, 349, 1360-1368.	27.0	692
167	Irritable bowel syndrome: evaluation and treatment. <i>Gastroenterology Clinics of North America</i> , 2003, 32, 507-529.	2.2	14
168	Alosetron in Irritable Bowel Syndrome. <i>Drugs</i> , 2003, 63, 1895-1905.	10.9	24
169	A novel endoscopic full-thickness plicator for the treatment of GERD: a pilot study. <i>Gastrointestinal Endoscopy</i> , 2003, 58, 770-776.	1.0	86